Biotech Startups

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing. It focuses on treating the underlying causes of hearing loss, including genetic hearing loss.

6 investors

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.

6 investors

Algorithmiq develops quantum algorithms that combine classical and quantum computers to solve problems in chemistry and life sciences, with a focus on drug discovery and development for rare diseases. Its products include a quantum computer interface and proprietary quantum chemistry algorithms applicable to materials, drugs, and energy.

6 investors

Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.

6 investors

A venture studio embedded within Alloy Therapeutics that partners with academics, entrepreneurs, pharma companies, and VCs to create and develop early-stage drug discovery companies. It gives its portfolio companies access to Alloy's discovery technologies and enabling services, and support in strategy, legal, R&D funding, and partnerships to reach Series A financing.

6 investors

ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.

6 investors

Amai develops novel proteins through precision fermentation, starting with a sweet protein derived from nature that can reduce sugar in food products by 40-70% while maintaining taste. The company targets food manufacturers seeking sustainable sugar alternatives.

6 investors

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders. It targets diseases with significant unmet medical needs.

6 investors

Ancilia is a biotech company using CRISPR to create beneficial bacterial products, such as live biotherapeutics, that carry immunity against the viruses that destroy them. It develops computational and biological platforms to identify, characterize, and counter viruses within the microbiome (the virome).

6 investors

Antarka develops a skin-permeable enzyme derived from Antarctic organisms that repairs UV-induced DNA damage, offered as a high-purity active ingredient for cosmetic brands to formulate into anti-aging creams, sunscreens, and repair serums. The company operates in the biotech and dermocosmetics space, supplying formulators rather than selling finished consumer products directly.

6 investors

Apoha develops technology that measures a new layer of molecular data governing how biologics behave and how products perform, positioning itself as a data layer for AI. It serves industries that depend on the predictable behavior of matter, with applications including biologics/antibody design and analysis of food systems.

6 investors

6 investors

Aromyx develops biosensor technology that replicates human olfactory receptors to measure and quantify odors and flavors for product development, quality control, and consumer targeting across food, beverage, sustainability, and health industries.

6 investors

Arpeggio Bio is a pharmaceutical company that uses AI and high-throughput RNA-sequencing to develop drugs targeting transcription factors, including historically "undruggable" proteins such as NRF2, TEAD, and GPX4. Its lead program targets IO-resistant melanoma, and it has worked on rare disease and inflammation programs through partnerships.

6 investors

Artos provides AI-powered software tools for Chemistry, Manufacturing, and Controls (CMC) teams in the pharmaceutical industry to draft, manage, and quality-check regulatory documentation. The platform uses specialized AI systems designed to handle dense tabular data and non-standard formats common in regulatory Module 3 documents.

6 investors

Asimov develops a computer-aided design platform for genetic engineering, enabling designers to program living cells by applying abstraction, standardization, and modeling to biology. The company serves genetic engineers and biotechnology researchers building engineered biological systems.

6 investors

AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics. Its programs target areas such as Alzheimer's disease, sleep, and other CNS disorders.

6 investors

Ataraxis develops AI foundation models that analyze multi-modal patient data, including pathology slide images, to assess cancer aggressiveness and predict recurrence risk and treatment response. Its first product, Ataraxis Breast, provides clinically validated prognostic and predictive tools for breast cancer patients and their physicians.

6 investors

Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS. Founded as a spin-off from VIB and KU Leuven, it focuses on drug development for currently untreatable complex neurological diseases.

6 investors

Auxilius provides software and expert services to manage clinical R&D operations and financial processes for biotech companies. The platform automates budgeting, forecasting, and financial close procedures to reduce clinical trial failures caused by operational complexity.

6 investors

Avant develops cultivated animal protein as an alternative to wild-caught fish, aiming to produce seafood protein without contaminants such as heavy metals, microplastics, and parasites. The company operates in the cultivated/cell-based foodtech space and is building pilot production capacity.

6 investors

Avantium develops bio-based materials and polymer technologies, including PEF and other renewable alternatives to conventional plastics, serving the packaging and materials industry.

6 investors

Avedro is an ophthalmic company focused on corneal health, known for bio-activated cross-linking therapies such as the KXL system and riboflavin-based treatments used to address progressive keratoconus. It was acquired in 2019 by Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company developing glaucoma, corneal and retinal therapies, and now operates as part of Glaukos, whose website the avedro.com domain serves.

6 investors

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It is a spinout from King's College London research focused on the genetics and molecular biology of these diseases.

6 investors